The Medicines Company declares positive results from Inclisiran trial
Category: #health  By Nikita Chaurasia  Date: 2019-08-28
  • share
  • Twitter
  • Facebook
  • LinkedIn

The Medicines Company declares positive results from Inclisiran trial
  • The ORION-11 trial of inclisiran sodium 300 mg reached all secondary and primary endpoints with efficacy that is consistent with the findings from Phase 2 and 1 trials.
     
  • The trial evaluated that inclisiran was tolerated well and confirmed that its safety profile was as favorable as that shown in the ORION-3 and ORION-1 Phase 2 open-label extension studies.

The Medicines Company, a biopharmaceutical company dedicated to halt atherosclerosis progression and reduce cardiovascular risk, reportedly announced the positive topline outcomes of the first Phase 3 clinical trial examining the safety, tolerability and efficacy of inclisiran to reduce LDL-cholesterol by taking doses twice a year.

The ORION-11 trial of inclisiran sodium 300 mg reached all secondary and primary endpoints with efficacy that is consistent with findings from Phase 2 and 1 trials. The trial evaluated that inclisiran was tolerated well and confirmed that its safety profile was as favorable as that shown in the ORION-3 and ORION-1 Phase 2 open-label extension studies.

Detailed safety, tolerability and efficacy data from ORION-11 would be presented at a science session being conducted at the European Society of Cardiology’s ESC Congress 2019 in Paris on the 2nd of September at 8:30 am Central European Time (CET).

Mark Timney, CEO at The Medicines Company stated that it is an important occasion that strengthens the company’s confidence on in the immense potential of inclisiran to radically change cardiovascular disease treatment.

Mark added that he was proud of the company’s clinical development department’s commitment to quickly and efficiently develop this top-quality investigational therapy which could help millions of patients of ASCVD to attain treatment goals, have healthier lives and live longer.

This global study took place at 70 different sites across seven countries, ex-U.S. Each trial participant was given inclisiran sodium 300 mg, initially given as a subcutaneous injection, then again after three months and every six months after first three months.

 

Source Credit: https://www.themedicinescompany.com/investor/pr/3992694/

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Nikita Chaurasia    

Nikita Chaurasia

Having always been daft at wordplay, Nikita Chaurasia, post the completion of post-graduation, commenced her journey into the content generation cosmos. Endowed with a professional MBA degree in Advertising and Public Relations, Nikita strives to integrate her creativ...

Read More

More News By Nikita Chaurasia

Amazon adds indoor surveillance drone to security solutions portfolio
Amazon adds indoor surveillance drone to security solutions portfolio
By Nikita Chaurasia

  This is the next big launch after the announcement of car security devices Indoor drone will offer video surveillance in places devoid of static cameras U.S.-based multinational technology giant, Amazon.com Inc. along with Ring Inc. has ...

JPMorgan to move USD 234 billion worth assets to Germany before Brexit
JPMorgan to move USD 234 billion worth assets to Germany before Brexit
By Nikita Chaurasia

  JPMorgan indicated plans to expand its hub in Paris by reassigning services based in London post Brexit The bank plans on completing the migration of its assets to the Frankfurt subsidiary by the end of 2020 As per reliable sources, Amer...

Nike plans to exit brick & mortar stores, records mega returns online
Nike plans to exit brick & mortar stores, records mega returns online
By Nikita Chaurasia

U.S.-based multinational sports apparel firm, Nike Inc., has reportedly revealed a significant upturn in their digital sales amid the COVID-19 pandemic, recording a revenue of USD 10.6 billion. Sources close to the matter claim that the company plans...